Sugi Predict

Sugi Predict / Compounds / SCHEMBL5326602

SCHEMBL5326602

SCHEMBL5326602

Cc1cccc(CC(N)C(=O)O)c1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 4/20 0.53
▸ NOS1 P29475 4/20 0.53
▸ NOS2 P35228 4/20 0.53
▸ SLC7A5 Q01650 6/20 0.50
▸ PKM P14618 2/20 0.50
▸ ALPI P09923 1/20 0.50
▸ PTGS1 P23219 1/20 0.50
▸ XIAP P98170 1/20 0.50
▸ MAPT P10636 3/20 0.46
▸ USP2 O75604 2/20 0.46
▸ HIF1A Q16665 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ BLM P54132 2/20 0.46
▸ PMP22 Q01453 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ RECQL P46063 2/20 0.46
▸ RGS12 O14924 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9188703 1.00 NOS3 (0.53) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL30013065 1.00 NOS3 (0.53) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL34461657 1.00 NOS3 (0.53) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL28310658 0.86 NOS3 (0.42) NOS3NOS1NOS2MAPTALDH1A1
SCHEMBL29379111 0.86 NOS3 (0.59) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL43865 0.86 NOS3 (0.59) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL43864 0.86 NOS3 (0.59) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL383453 0.86 NOS3 (0.59) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL2031548 0.85 NOS3 (0.51) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL2032640 0.85 NOS3 (0.51) NOS3NOS1NOS2SLC7A5PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US claimed
EP-4594336-A2 EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME PeptiDream Inc. (JP) 2025-08-06 — — EP disclosed
WO-2024073605-A2 EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME PEPTIDREAM INC. (JP) 2024-04-04 — — WO disclosed
EP-3061753-A1 ENANTIO-SELECTIVE SYNTHESIS OF NON-NATURAL AMINO ACIDS Universita' Degli Studi "G. d'Annunzio" Chieti-Pescara (IT) 2016-08-31 — — EP disclosed
WO-2007002469-A2 THERAPEUTIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS BHATNAGAR RAJENDRA S (US) 2007-01-04 — — WO disclosed
US-20060293228-A1 Therapeutic compositions and methods using transforming growth factor-beta mimics BHATNAGAR RAJENDRA S 2006-12-28 — — US disclosed
US-20060293227-A1 Cosmetic compositions and methods using transforming growth factor-beta mimics BHATNAGAR RAJENDRA S 2006-12-28 — — US disclosed
US-6939854-B2 Peptide inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-09-06 — — US disclosed
US-6846806-B2 Peptide inhibitors of Hepatitis C virus NS3 protein BRISTOL-MYERS SQUIBB COMPANY (US) 2005-01-25 — — US disclosed
US-6774212-B2 FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-08-10 — — US disclosed
US-20040147483-A1 Peptide inhibitors of hepatitis C virus NS3 protease PRIESTLEY E SCOTT (DE) 2004-07-29 — — US disclosed
US-6699855-B2 PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2004-03-02 — — US disclosed
US-20020177725-A1 Peptide inhibitors of hepatitis C virus NS3 protein BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) 2002-11-28 — — US disclosed
US-20020123468-A1 Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-09-05 — — US disclosed
US-20020065248-A1 Inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-30 — — US disclosed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US disclosed
EP-0787010-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-06 — — EP disclosed
WO-1996012499-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-02 — — WO disclosed
EP-0677060-A1 PEPTIDE INHIBITORS OF CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 1995-10-18 — — EP disclosed
WO-1994015958-A2 PEPTIDE INHIBITORS OF CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 1994-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065248-A1 Inhibitors of hepatitis C virus NS3 protease TMPRSS15, CTRC, CPN1 NOS3 1087/4885NOS1 1567/4885NOS2 2393/4885
US-20020177725-A1 Peptide inhibitors of hepatitis C virus NS3 protein VIP, PRSS1, SERPINB1 NOS3 2450/4885NOS1 2032/4885NOS2 3288/4885
US-20040147483-A1 Peptide inhibitors of hepatitis C virus NS3 protease VIP, PRSS1, CTSC NOS3 2269/4885NOS1 1945/4885NOS2 3330/4885
US-20020123468-A1 Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease CES1, CYP51A1, SPINT2 NOS3 1939/4885NOS1 2114/4885NOS2 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.